Full-Life Technologies Secures $150M for Radiotherapy

Full-Life Technologies, a company operating in the radiotherapy space, has secured a total of $150 million in fresh capital, according to a report from Endpoints News. The raise was structured across two separate tranches: a Series D round of $110 million, followed by an additional $40 million that brought the cumulative figure to $150 million.

A Staged Capital Strategy

The two-part structure of the fundraise reflects a pattern increasingly seen among clinical-stage companies seeking to manage dilution while maintaining access to capital as development milestones are reached. Full-Life Technologies did not publicly disclose the specific allocation of proceeds across the two tranches, though radiotherapy programs typically require substantial infrastructure investment alongside clinical trial expenditure.

Radiotherapy as a field has attracted growing investor attention in recent years, driven in part by advances in targeted isotope delivery and the expansion of radioligand therapy pipelines across the broader oncology sector. Full-Life Technologies operates within this landscape, though Endpoints News did not detail the company's specific pipeline assets or clinical stage in the reported summary.

Quince Pivots Toward Pulmonary

Separately, Quince — a biopharmaceutical company that has undergone a strategic reorientation — is reported to be rebooting its operations around a pulmonary drug program. The nature of the asset and the stage of development were not elaborated upon in the source reporting, but the pivot signals a meaningful shift in the company's therapeutic focus.

Strategic reboots of this kind are not uncommon in the biopharmaceutical industry, where companies facing setbacks in one therapeutic area may redirect resources toward programs with stronger near-term data or commercial potential. Pulmonary medicine has remained an active area of drug development, with a range of conditions — from rare interstitial lung diseases to more prevalent respiratory disorders — drawing pipeline investment.

Other Industry Movements

The Endpoints News report also noted activity involving several other companies, including Accro Bioscience, Hansa Biopharma, Shanghai Best-Link Bioscience, and UCB, though detailed disclosures regarding their specific developments were limited in the available summary. These mentions reflect the broader cadence of deal-making, partnerships, and regulatory activity that characterises the clinical-stage biopharma sector on a week-to-week basis.

Full-Life Technologies' $150 million raise stands as one of the more substantial single-company fundraises in the radiotherapy segment reported in recent coverage, underscoring continued institutional appetite for companies developing precision oncology platforms. Whether the capital will accelerate existing trials or fund new programme initiations remains to be seen as the company provides further updates.